01—Abstract
Summary
Summary of the 10-Q filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
McKesson Corporation reported an increase in revenues for the three months ended June 30, 2026, driven by growth in its North American Pharmaceutical and Oncology & Multispecialty segments.
While revenue rose by 8% year-over-year to $105.4 billiona, net income attributable to McKesson Corporation saw a significant decrease of 22% to $614 million, resulting in diluted earnings per share of $5.15, down from $6.25 in the prior year period. The company's financial performance was impacted by various factors, including higher operating expenses, increased interest expense due to new debt facilities, and a substantial increase in restructuring, impairment, and related charges, which more than doubled compared to the prior year. Despite these pressures, McKesson continued its capital return program, repurchasing $2.5 billion in stock and paying $102 million in dividends, and announced an increase in its quarterly dividend.
02—Key points
Key Highlights
- Revenues increased by 8% to $105.4 billion, driven by growth in North American Pharmaceutical and Oncology & Multispecialty segments.
- Net income attributable to McKesson Corporation decreased by 22% to $614 million ($5.15 diluted EPS), compared to $784 million ($6.25 diluted EPS) in the prior year.
- Operating expenses increased by 5% to $2.4 billion, largely due to higher restructuring charges, which rose from $47 million to $136 million.
- Interest expense rose significantly by 57% due to increased average debt balances, notably from new term loans for the Medical-Surgical Solutions segment.
- McKesson returned $2.6 billion to shareholders through $2.5 billion in share repurchases and $102 million in dividends.
- The company announced an increase in its quarterly dividend to $0.94 per share, up from $0.82.
- A 13% minority interest in the Medical-Surgical Solutions business was sold to Apollo Funds for approximately $1.25 billion as part of a separation strategy.
03—Questions
Frequently Asked Questions
What was the primary driver for the revenue increase?
The revenue increase of 8% to $105.4 billion was primarily driven by market growth in the North American Pharmaceutical segment, including higher volumes from institutional healthcare providers and retail national account customers, as well as growth in the Oncology & Multispecialty segment due to higher specialty pharmaceutical sales.
Why did net income attributable to McKesson Corporation decrease significantly?
Net income attributable to McKesson Corporation decreased by 22% to $614 million primarily due to a significant increase in operating expenses, including higher restructuring, impairment, and related charges which more than doubled year-over-year. Increased interest expense from new debt facilities and higher net income attributable to noncontrolling interests also contributed to the decline.
What is the company doing with its Medical-Surgical Solutions segment?
McKesson is pursuing a strategy to separate its Medical-Surgical Solutions business into an independent company. As a step in this process, McKesson sold a 13% minority interest in this segment to Apollo Funds for approximately $1.25 billion in convertible preferred equity on June 1, 2026. McKesson retains operating control and majority ownership.
How is McKesson managing its capital structure and returning value to shareholders?
McKesson raised approximately $3.2 billion in new debt facilities for its Medical-Surgical Solutions segment and refinanced its revolving credit facilities to a $5.0 billion senior unsecured facility. The company actively returned capital to shareholders, repurchasing $2.5 billion of its stock and paying $102 million in dividends during the quarter. Furthermore, the Board approved an additional $5.0 billion share repurchase authorization and raised the quarterly dividend to $0.94 per share.
04—Continue